Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
05
11
2018
accepted:
28
03
2019
pubmed:
6
4
2019
medline:
8
7
2020
entrez:
6
4
2019
Statut:
ppublish
Résumé
Quality of response to immunosuppressive therapy and long-term outcomes for pediatric severe aplastic anemia remain incompletely characterized. Contemporary evidence to inform treatment of relapsed or refractory severe aplastic anemia for pediatric patients is also limited. The clinical features and outcomes for 314 children treated from 2002 to 2014 with immunosuppressive therapy for acquired severe aplastic anemia were analyzed retrospectively from 25 institutions in the North American Pediatric Aplastic Anemia Consortium. The majority of subjects (n=264) received horse anti-thymocyte globulin (hATG) plus cyclosporine (CyA) with a median 61 months follow up. Following hATG/CyA, 71.2% (95%CI: 65.3,76.6) achieved an objective response. In contrast to adult studies, the quality of response achieved in pediatric patients was high, with 59.8% (95%CI: 53.7,65.8) complete response and 68.2% (95%CI: 62.2,73.8) achieving at least a very good partial response with a platelet count ≥50×10
Identifiants
pubmed: 30948484
pii: haematol.2018.206540
doi: 10.3324/haematol.2018.206540
pmc: PMC6886407
doi:
Substances chimiques
Antilymphocyte Serum
0
Cyclosporine
83HN0GTJ6D
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1974-1983Subventions
Organisme : NIDDK NIH HHS
ID : R24 DK099808
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001102
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright© 2019 Ferrata Storti Foundation.
Références
J Pediatr (Rio J). 2014 Sep-Oct;90(5):523-7
pubmed: 24878006
Blood. 2000 Mar 15;95(6):1931-4
pubmed: 10706857
Haematologica. 2011 Jun;96(6):814-9
pubmed: 21422115
N Engl J Med. 2017 Apr 20;376(16):1540-1550
pubmed: 28423296
N Engl J Med. 1982 Mar 25;306(12):712-8
pubmed: 7038485
Blood. 1995 Jun 1;85(11):3058-65
pubmed: 7756640
Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S119-25
pubmed: 19782144
Semin Hematol. 2000 Jan;37(1):91-101
pubmed: 10676914
N Engl J Med. 2011 Aug 4;365(5):430-8
pubmed: 21812672
Br J Haematol. 2000 Oct;111(1):321-8
pubmed: 11091219
Klin Padiatr. 1998 Jul-Aug;210(4):173-9
pubmed: 9743949
Haematologica. 2014 Dec;99(12):1784-91
pubmed: 25193958
JAMA. 2010 Sep 22;304(12):1358-64
pubmed: 20858879
Blood. 2008 Feb 1;111(3):1054-9
pubmed: 17989314
JAMA. 2003 Mar 5;289(9):1130-5
pubmed: 12622583
Br J Haematol. 2012 May;157(3):339-46
pubmed: 22372373
Haematologica. 2014 Oct;99(10):1574-81
pubmed: 25085353
Pediatr Blood Cancer. 2014 May;61(5):869-74
pubmed: 24285674
Blood. 2007 Sep 1;110(5):1439-47
pubmed: 17468339
Br J Haematol. 2015 May;169(4):565-73
pubmed: 25683884
N Engl J Med. 1982 Mar 18;306(11):645-52
pubmed: 7035946
J Pediatr. 2008 Dec;153(6):814-9
pubmed: 18672253
Blood. 2000 Sep 15;96(6):2049-54
pubmed: 10979946
Lancet Haematol. 2015 Sep;2(9):e367-75
pubmed: 26685770
N Engl J Med. 1991 May 9;324(19):1297-304
pubmed: 2017225
Int J Hematol. 2016 Aug;104(2):168-74
pubmed: 27278666